Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Anticancer Res. 2020 Dec;40(12):6971-6978. doi: 10.21873/anticanres.14721. Epub 2020 Dec 7.
BACKGROUND/AIM: We retrospectively investigated the significance of pre-treatment interferon-gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint inhibitor treatment (ICI-tx).
This study included non-small-cell lung cancer patients who received ICI-tx between January 1, 2016 and April 30, 2019. IGR was measured using the positive control of an enzyme-linked immunosorbent assay. We defined the pre-treatment cut-off level of IGR as 10 IU/ml.
Fifty-four patients were divided into two groups; those with an IGR ≤10 IU/ml (lower group: LG) (n=15) and those with >10 IU/ml (higher group: HG) (n=39). The time to treatment failure (TTF) in the HG was significantly longer than that in the LG. In multivariate analyses, C-reactive protein and IGR levels were significant risk factors for TTF.
Pre-treatment IGR level of >10 IU/ml is recommended to identify those patients who will respond favourably to ICI-tx.
背景/目的：我们回顾性研究了治疗前干扰素-γ释放（IGR）作为预测免疫检查点抑制剂治疗（ICI-tx）疗效的生物标志物的意义。
本研究纳入了 2016 年 1 月 1 日至 2019 年 4 月 30 日期间接受 ICI-tx 的非小细胞肺癌患者。IGR 采用酶联免疫吸附测定的阳性对照进行测量。我们将 IGR 的治疗前截断值定义为 10IU/ml。
54 例患者分为两组；IGR≤10IU/ml（低组：LG）（n=15）和>10IU/ml（高组：HG）（n=39）。HG 的治疗失败时间（TTF）明显长于 LG。多变量分析显示，C 反应蛋白和 IGR 水平是 TTF 的显著危险因素。
建议治疗前 IGR 水平>10IU/ml 以识别对 ICI-tx 反应良好的患者。
